GoodRx Holdings, Inc. is a consumer-focused digital healthcare platform in the United States that provides price transparency and affordability solutions for prescription medications. The company operates a prescription marketplace offering dynamic, geographically relevant pricing and access to negotiated discounts through GoodRx codes for both generic and brand drugs. Its subscription services, including Gold and RxSmartSaver+, provide lower prices on select medications, mail delivery, and access to GoodRx Care telehealth services. The platform also offers condition-specific end-to-end solutions that bundle clinician visits, prescriptions, and delivery. GoodRx serves consumers, healthcare providers, pharmacies, and pharma manufacturers, partnering with the latter to integrate affordability solutions such as co-pay cards and patient assistance programs. The company also provides educational resources and medication information to users. It operates primarily in the U.S. market, processing pricing data to facilitate transactions across the healthcare ecosystem.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Health Information Services Homepage goodrx.com
Sector Healthcare IR page investors.goodrx.com
Tags
prescription price comparison, telehealth, pharma direct, subscription services, medication adherence, digital healthcare, consumer healthcare, price transparency, GoodRx, Gold, RxSmartSaver+, GoodRx Care, Provider Mode
Press page —

Metrics

Valuation  
Market cap $ 1.119B
Market cap (USD) $ 1.119B
P/E 68.87
PEG —
P/BV 1.73
P/S 1.43
P/OCF 5.55
P/FCF 5.68
Dividend yield —
Turnover / mcap —
Returns  
ROE 4.5%
ROI 2.8%
ROIC 4.3%
Profit margin 3.8%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 75.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 22
Quality score 23.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 796.853M 792.324M 750.265M 766.554M 745.424M 550.7M 388.224M
Net profit 30.439M 16.39M -8.868M -32.828M -25.254M -293.623M 66.048M
Free cash flow 164.383M 182.652M 137.249M 142.813M 174.208M 110.788M 81.861M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 2.71 4.65 6.7 4.66 32.68 40.34 35.91
Price performance 12m -0.42 -0.31 0.44 -0.86 -0.19 0.12 —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 48.1M 68.7M 118M 117M 144M 146M 236M
↳ YoY growth +42.8% +71.8% -0.8% +22.6% +1.6% +61.5%
↳ 5y CAGR +24.8% +28.0%
Borrowings, current (USD) — 7.03M 7.03M 7.03M 7.03M 8.79M 5M 5M
Borrowings, non-current (USD) — 664M 660M 656M 652M 648M 487M 483M
Lease liabilities (USD) — 40.1M 38M 39.4M 58.2M 54.6M 51.7M 54.5M
Cash and deposits (USD) 34.6M 26.1M 969M 941M 757M 672M 448M 262M
Intangible assets (USD) — 21.3M 36.9M 88.8M 120M 60.9M 52.1M 64.1M
Right-of-use assets (USD) — 32.3M 27.7M 27.7M 35.9M 29.9M 27.8M 28.8M
Net debt (borrowings + leases - cash) (USD) — 685M -264M -239M -40.1M 38.8M 95M 281M
Cash flow detail
Operating cash flow (USD) 45.3M 83.3M 131M 179M 147M 138M 184M 168M
Purchases of property, plant and equipment (USD) -804,000 -1.43M -20.6M -4.57M -3.97M -1.04M -1.24M -3.52M
Purchases of intangible assets (USD) -2.65M -4.32M -15.3M -29.9M -51.2M -54.7M -69.1M -70.5M
Change in receivables (cash effect) (USD) -12.8M -14.5M -16.1M -43.9M 1.38M -26.5M -2.33M -88M
Change in payables (cash effect) (USD) 665,000 515,000 2.15M 4.21M -874,000 17.5M -21.2M 4.1M
Dividends paid (cash effect) (USD) -1.35B — — — — — — —
Share buybacks (cash effect) (USD) — — 0.00 0.00 -102M -104M -159M -216M
Interest paid (cash effect) (USD) -18.7M -48.4M -24.5M -20.2M -30.7M -48.8M -55.1M -40.8M
Income taxes paid (cash effect) (USD) -11.7M -19.4M -29.2M -18.1M -4.36M -17.2M -23.6M -13.1M
Share-based compensation (USD) 1.76M 3.75M 397M 160M 120M 105M 99M 76.6M
Operating cash flow before change in receivables (USD) 58.1M 97.8M 147M 223M 145M 165M 186M 256M
Free cash flow (OCF - PPE - intangibles) (USD) 41.8M 77.5M 95.5M 144M 91.6M 82.5M 114M 93.9M
Income detail
Research and development expense (USD) 43.9M 29.3M 61.8M 126M 143M 136M 124M 121M
↳ 5y CAGR +25.3% +33.4% +14.4%
Total comprehensive income (USD) — 0.00 0.00 0.00 — — — —
Comprehensive income to owners (USD) — 0.00 0.00 0.00 — — — —
Reported Mar 12, 2021 Mar 12, 2021 Mar 1, 2023 Mar 1, 2023 Mar 1, 2023 Feb 29, 2024 Feb 27, 2025 Feb 26, 2026

Operating KPIs — quarters

KPI Sep 24 Dec 24 Mar 25 Jun 25 Sep 25 Dec 25 Mar 26 Jun 26
Monthly active users 6.5M 6.6M 6.4M 5.7M 5.4M 5.3M 5.3M 5M
↳ YoY growth -4.5% -13.6% -16.9% -19.7% -17.2% -12.3%
Reported Nov 4, 2025 Nov 4, 2025 Nov 4, 2025 Nov 4, 2025 Nov 4, 2025 May 6, 2026 May 6, 2026 Aug 5, 2026

Operating KPIs — years

KPI Dec 2024 Dec 2025
Monthly active users 6.6M 5.3M
↳ YoY growth -19.7%
Reported Feb 25, 2026 May 6, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

GoodRx Launches Employer Direct Weight Loss Offering Bull 3 Bear 0 Product/operations

Oct 29, 2026

PDF Version

Early demand signals a shift toward flexible GLP-1 benefit models that help employers support employee access and transparent costs

Brief Summary:

  • GoodRx Employer Direct weight loss offering is now available

  • Employers select eligible GLP-1 medications, set contribution levels, and can add clinical care through GoodRx for Weight Loss

  • Employer Direct provides access to employer pricing made available by manufacturers for Wegovy®, Wegovy HD®, Wegovy® pill, Foundayo™ and Zepbound® KwikPen®

  • GoodRx collaborates with Novo on employer pricing and is an approved independent program administrator for Lilly Employer Connect

SANTA MONICA, Calif.--(BUSINESS WIRE)--Oct. 29, 2026-- GoodRx (Nasdaq: GDRX), the trusted platform for prescription access and affordability in the U.S., today announced the market-wide launch of its Employer Direct weight loss offering, giving employers a flexible way to help employees access and afford FDA-approved GLP-1 medications. As demand for these treatments grows, employers are looking for new ways to support access outside the traditional pharmacy benefit. Employer Direct allows employers to choose which medications to include and how much to contribute, giving them greater control over benefit costs while lowering what eligible employees pay out of pocket.

“For many employers, the question is not whether they want to support GLP-1 access, but how to make it affordable for employees and manageable within their benefits budgets,” said Wendy Barnes, President and CEO of GoodRx. “GoodRx Employer Direct creates a model that combines manufacturer-sponsored employer pricing with flexible employer funding, care, and fulfillment. It gives employers greater control, creates a clearer path to treatment for employees, and extends GoodRx’s access platform into a significant new channel.”

“The value of employer-sponsored access depends on making treatment easy for employees to obtain,” said Tom Scales, Senior Vice President, Market Access and Public Affairs at Novo. “Through our work with GoodRx, Wegovy pricing for employer programs will be available at retail pharmacies nationwide, giving employers a scalable way to support access and employees a familiar, convenient way to fill their prescriptions.”

A Weight Loss Benefit Employers Can Tailor

Employer Direct is designed to complement an employer's existing health plan by providing targeted support for medications that may not otherwise be covered within the traditional benefit. Employers can configure the offering based on the needs of their workforce and their benefits strategy, with implementation as quick as 30 days:

  • Choose the medications: Employers determine which eligible FDA-approved GLP-1 medications for weight management to include in the offering. Medications include Wegovy®, Wegovy HD®, Wegovy® pill, Foundayo™ and Zepbound® KwikPen®.

  • Set the contribution: Employers choose how much to contribute toward pricing made available by manufacturers for employer programs, whether as a fixed amount, a percentage, or full coverage. Contributions are applied automatically when prescriptions are filled, with no reimbursement required.

  • Add clinical care: Employers can integrate GoodRx for Weight Loss into the offering, connecting clinical care, transparent pricing on FDA-approved therapies, and pharmacy fulfillment in one streamlined experience. Employees can also participate with a valid prescription from their own healthcare provider.

“Our Team Members want access to GLP-1 medications, so we sought a solution that could meet that need without increasing cost uncertainty,” said Theresa Richardson, Chief Talent Officer at Withum. “We chose GoodRx Employer Direct because it provides access to manufacturer-direct pricing, along with the flexibility to determine which medications to support and how much to contribute. This allows us to offer a benefit with predictable costs while giving our Team Members a straightforward path to treatment.”

“Employers need confidence that a new benefit will work in practice for both their organization and their employees,” said Norman Lewis, Partner and Senior Vice President at USI Insurance Services. “We recommend GoodRx Employer Direct because it combines established manufacturer relationships with access through a simple and reliable platform. That combination gives our clients optionality and better transparency than through their health plan provider.”

Bringing GoodRx’s Access Platform to Employers

Employer Direct extends GoodRx’s access platform to plan sponsors by bringing together the manufacturer relationships built through Pharma Direct, the subscription and care capabilities behind GoodRx for Weight Loss, and GoodRx’s nationwide retail pharmacy network and select mail order partners. The offering gives organizations of all sizes access to manufacturer pricing, with GoodRx serving as an approved independent program administrator for Lilly Employer Connect and working directly with Novo for employer pricing. The result is an integrated experience that connects net pricing, care, and fulfillment at scale.

GoodRx Companion Coming to Employer Direct January 2027

Beginning January 2027, employers will also be able to offer GoodRx Companion through Employer Direct. The fixed monthly subscription provides free and low-cost generic medications and savings on common healthcare services, including dental, vision, labs and imaging. Employers can offer Companion on its own or alongside the weight loss offering, giving small businesses, unions, and companies with large contractor or part-time workforces another way to extend healthcare savings to more of their workforce.

Employers, plan sponsors, consultants, and third-party administrators interested in learning more about Employer Direct should visit: www.goodrx.com/employerdirect.

About GoodRx

GoodRx is the trusted platform for prescription access and affordability. The company helps consumers navigate care, cost, and fulfillment so they can start and stay on treatment, while enabling partners to deliver self-pay pricing, affordability programs, and pharmacy access at scale. With a trusted brand, nationwide pharmacy network, and more than 280 million annual site visits, GoodRx reaches consumers at the moments when cost and access are shaping healthcare decisions. Since 2011, GoodRx has helped Americans save over $100 billion on medications.

​GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.

GoodRx Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings, convenience and accessibility; the expected benefits, pricing and value of GoodRx Employer Direct; and our plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

News Release image

View source version on businesswire.com: https://www.businesswire.com/news/home/20261029410878/en/

Media Contact [email protected]

Source: GoodRx

Review On October 27, 2026, the Audit and Risk Committee of the Board of Directors (the “Board”) of GoodRx Holdings, Inc. (the “Company”), after discussion with management of the Company and the Company’s independent registered public accounting firm, KPMG LLP (“KPMG”), concluded that the Company’s condensed consolidated financial statements for the fiscal quarter and year-to-date periods ended March 31, 2026 and June 30, 2026 (collectively, the “Affected Periods”) should no longer be relied upon due to the understatement of Pharma Direct revenue. Similarly, any previously issued or filed reports, press releases, earnings releases, and investor presentations or other communications describing the Company’s condensed consolidated financial statements and other related financial information for the Affected Periods should no longer be relied upon.

Sep 03, 2026

PDF Version

New $24.99 monthly plan includes a primary member and up to four dependents, including children, adults, and pets, with more than 250 generic medications available for free and savings on dental, vision, lab and imaging services

Brief Summary:

  • GoodRx launched the Companion Family Plan for $24.99 per month or $16.99 per month when paying annually

  • The plan covers a primary member and up to four dependents, including children, adult family members, and pets, with no age restrictions

  • Members can access more than 250 eligible medications for free and hundreds more for under $10 at nearly every pharmacy nationwide, along with savings on dental, vision, lab, and imaging services

  • The plan broadens GoodRx's subscription offering, supports prescription volume and patient retention for retail pharmacy partners, and is expected to become available to employers through GoodRx Employer Direct

SANTA MONICA, Calif.--(BUSINESS WIRE)--Sep. 3, 2026-- GoodRx (Nasdaq: GDRX), the trusted platform for prescription access and affordability in the U.S., today launched the GoodRx Companion Family Plan, expanding its everyday healthcare subscription to the entire family, including pets. As widening coverage gaps and rising out-of-pocket costs leave households paying more for care, the new plan brings Companion’s free and low-cost prescriptions and savings on common healthcare services together in one affordable, predictably priced membership.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903790974/en/

News Release image

“Families don’t experience healthcare costs one person at a time. They’re simultaneously managing prescriptions and care for kids, parents, partners, and even pets,” said Wendy Barnes, President and CEO of GoodRx. “Expanding Companion across the entire household allows us to support consumers in a way that reflects this reality. It also advances our strategy to make GoodRx a more central part of how consumers navigate and pay for healthcare.”

One Plan. More Ways for Families to Save.

The Companion Family Plan, which costs $24.99 per month or $16.99 per month when paying annually, extends Companion benefits to a primary member and up to four dependents, which may include children, adult family members, and pets. Members can access more than 250 eligible generic medications for free and hundreds more for under $10 at nearly every pharmacy nationwide, plus savings on dental, vision, lab and imaging services. The primary member also receives access to $19 online care visits. Together, these features give families an affordable and predictable way to save across prescriptions and common healthcare needs.

Building a Broader Subscription Offering

The Companion Family Plan expands the reach and value of GoodRx’s subscription offering, creating a more continuous way to support consumers beyond individual prescription transactions. Building on more than a decade of medication pricing expertise, extensive retail pharmacy relationships, and a trusted consumer brand, GoodRx is uniquely positioned to bring this model to scale. Companion complements the company’s condition-focused offerings for weight loss, erectile dysfunction, and hair loss.

Supporting Growth and Retention for Retail Pharmacy Partners

Companion gives members access to meaningfully lower prices than they would receive through a traditional prescription discount, while allowing them to continue filling at the pharmacies they already know and trust. This helps retail pharmacy partners strengthen patient relationships, support prescription volume, and deliver a more compelling consumer experience, with no additional cost to participate. The Companion Family Plan broadens those benefits while preserving favorable pharmacy economics and reinforcing the value of GoodRx’s retail pharmacy network.

Making Companion an Employee Benefit

GoodRx plans to offer Companion through Employer Direct, giving employers a flexible, predictable way to subsidize memberships and help lower employees’ out-of-pocket healthcare costs. Companion can complement existing health benefits by addressing prescription costs and other coverage gaps, or extend healthcare savings to workers who are not eligible for traditional benefits. The expansion creates a new channel for Companion while giving employers another way to support healthcare affordability for their workforce.

To learn more, visit: www.goodrx.com/companion

About GoodRx

GoodRx is the trusted platform for prescription access and affordability. The company helps consumers navigate care, cost, and fulfillment so they can start and stay on treatment, while enabling partners to deliver self-pay pricing, affordability programs, and pharmacy access at scale. With a trusted brand, nationwide pharmacy network, and more than 280 million annual site visits, GoodRx reaches consumers at the moments when cost and access are shaping healthcare decisions. Since 2011, GoodRx has helped Americans save over $100 billion on medications.

​GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.

GoodRx Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings, convenience and accessibility; the expected benefits, pricing and value of GoodRx Companion Family Plan and related pricing; and our plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

News Release image

View source version on businesswire.com: https://www.businesswire.com/news/home/20260903790974/en/

Media Contact [email protected]

Source: GoodRx

Prompts

GoodRx Holdings, Inc. (ticker GDRX), listed in United States.

ETFs Holding GoodRx Holdings, Inc.

ETF Weight in ETF Shares Market value As of
DSMC 0.48% 214,489 $ 617.728K Jun 30, 2026
SQLV 0.38% 38,114 $ 109.768K Jun 30, 2026
AVSC 0.02% 166,535 $ 584.538K Nov 16, 2026
DFSV 0.02% 1,386,786 $ 4.868M Nov 12, 2026
DFAT 0.01% 877,300 $ 3.079M Nov 12, 2026
DXUV 0.00% 50,219 $ 176.269K Nov 12, 2026
DFAS 0.00% 258,615 $ 907.739K Nov 12, 2026
MSSM 0.00% 4,560 $ 15.914K Aug 31, 2026
DFSU 0.00% 14,700 $ 51.597K Nov 12, 2026
DFAC 0.00% 262,146 $ 920.132K Nov 12, 2026
DCOR 0.00% 54,238 $ 190.375K Nov 12, 2026
DFAU 0.00% 14,987 $ 52.604K Nov 12, 2026
DFUS 0.00% 12,843 $ 45.079K Nov 12, 2026